



67/2022/AR

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
<b>BioMaxima</b>	<b>Not rated</b>	<b>37.3</b>	<b>Not rated</b>	Sylwia Jaśkiewicz, CFA Mikołaj Stępień

**Event: January sales**

On Wednesday, at the beginning of WSE trading, the Company informed that in January, sales reached PLN 43.7 million which is a high figure (as compared with the unconsolidated sales for FY21 at PLN 78.5 million). January sales was supported by the ongoing execution of the contract for the delivery of tests for SARS-CoV-2 diagnostics worth PLN 94.8 million (BioMaxima informed about this contract at the beginning of January).

**Expected impact:** The contract for the delivery of SARS-CoV-2 tests worth PLN 94 million is executed expeditiously.

*The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.*